Biotech showed 85% patient improvement in Phase 2a trial--zero approved treatments exist for persistent concussion symptoms BOSTON, Jan. 7, 2026 /PRNewswire/ -- Oxeia Biopharmaceuticals today launched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback